ENTA discontinues EDP-305 for PBC indication following phase-2 miss on primary endpoint: https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Announces-Results-of-INTREPID-Study-of-EDP-305-for-the-Treatment-of-Primary-Biliary-Cholangitis/default.aspx PBC is a small indication and EDP-305 is a bad drug, so ENTA’s discontinuing this program is entirely justifiable.